株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アルツハイマー病:世界の治験動向

Alzheimer's Disease Global Clinical Trials Review, H1, 2020

発行 GlobalData 商品コード 222294
出版日 ページ情報 英文 1130 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.54円で換算しております。
アルツハイマー病:世界の治験動向 Alzheimer's Disease Global Clinical Trials Review, H1, 2020
出版日: 2020年05月08日 ページ情報: 英文 1130 Pages
概要

当レポートでは、アルツハイマー病治療薬に関する治験の最新動向について分析し、疾患・治療法の概要や、主なG7 (主要7カ国) 諸国およびE7 (新興7カ国) における治験の状況、地域・フェーズ (相)・段階別の進行状況、有望なスポンサー、各企業・研究機関の主力製品と治験の進行状況、有望な薬剤の比較、治験の現状・成果の最新情報、今後の進行見通し、といった情報を取りまとめてお届けいたします。

当レポートの概要

当レポートの分析範囲

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要5ヶ国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:中枢神経系疾患治療薬の治験におけるアルツハイマー病の比率

G7諸国での治験件数:相別 (フェーズ別)

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:中枢神経系疾患治療薬の治験におけるアルツハイマー病の比率

E7諸国での治験件数:相別 (フェーズ別)

E7諸国での治験件数:進捗状況別

相別の治験件数

  • 進行中の治験:相別

治験件数:進捗状況別

治験の目標の達成状況

一定期間に採用された被験者

治験件数:スポンサーの種類別

有望なスポンサー

  • アルツハイマー病治療薬の治験に参加している主要企業

有望な薬剤

アルツハイマー病治療薬:最新の治験動向

治験のプロファイル:概要

付録

図表

List of Tables

List of Tables

  • Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region, 2020*
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials In

List of Figures

List of Figures

  • Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region (%), 2020*
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2020*
  • Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2020*
  • Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2020*
  • Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase (%), 2020*
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2020*
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
  • GlobalData Methodology
目次
Product Code: GDHC6207CTIDB

GlobalData's clinical trial report, "Alzheimer's Disease Global Clinical Trials Review, H1, 2020" provides an overview of Alzheimer's Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Alzheimer's Disease
  • Mar 09, 2020: Study shows Nilvadipine slows early-stage Alzheimer's disease
  • Mar 05, 2020: AC Immune to present new data on neurodegenerative program ACI-35.030 at the Upcoming Advances in Alzheimer's and Parkinson's Therapies Focus Meeting
  • Mar 03, 2020: Alzheimer patients at Swedish clinics to be included in Phase 3 study of drug candidate BAN2401
  • Feb 27, 2020: Inflazome's Somalix demonstrates positive safety, tolerability and pharmacodynamic profile in its phase I study
  • Feb 26, 2020: ProMIS Neurosciences initiates natural history study of blood-based biomarkers in Alzheimer's Disease
  • Feb 20, 2020: Annovis issued patent for method of treating Parkinson's Disease and other lewy body diseases
  • Feb 14, 2020: Annovis Bio to continue DISCOVER Alzheimer's trial
  • Feb 12, 2020: Oligomerix presents preclinical data at TAU2020 Global Conference for small molecule inhibitor of tau self-association
  • Feb 11, 2020: Cassava Sciences announces Phase 2a study of PTI-125 published in the Journal of Prevention of Alzheimer's Disease (JPAD)
  • Feb 11, 2020: T3D Therapeutics begins enrollment in the PIONEER Phase 2 clinical trial of T3D-959 in patients with mild to moderate alzheimer's disease
  • Clinical Trial Profile Snapshots

Appendix

  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About GlobalData
  • Contact Us
  • Source